Spero Therapeutics (SPRO) Stock Forecast: StockMap's 2-Week Call
SPRO stock forecast: StockMap's model leans Underperform on Spero Therapeutics for the two weeks after the Nov 19 close, toward SPRO trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 4 of 6 two-week windows on SPRO since Aug 21; by chance, a call on the same dates was right 58% of the time.
Spero Therapeutics last closed at $0.83, -4.60% on the session.
Against the IVW growth benchmark the position is -2.27% over the forecast window.
Spero Therapeutics' market cap is $48.58M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -21 (too close to call).
Where SPRO sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 2 bullish and 13 bearish.
Agreement across those insights is 87%.
37 daily calls for SPRO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Spero Therapeutics in the 89th percentile on valuation and the 74th percentile on return on equity, where 100 is best.
Spero Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Spero Therapeutics as the 312th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Spero Therapeutics ranks 169th of 394 in the group, against a group median of -0.27.